MERS-CoV, influenza and other respiratory viruses among symptomatic pilgrims during 2014 Hajj season

Anwar M. Hashem¹² | Tagreed L. Al-Subhi¹ | Nassrin A. Badroon¹ | Ahmed M. Hassan¹ | Leena Hussein M. Bajrai¹³ | Talib M. Banassir⁴ | Khalid M. Alquthami⁴ | Esam I. Azhar¹⁵

¹Special Infectious Agent Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
²Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
³Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia
⁴Regional Laboratory, Ministry of Health, Makkah, Saudi Arabia
⁵Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia

Correspondence
Esam I. Azhar, Special Infectious Agent Unit, King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 128442, Jeddah 21362, Saudi Arabia.
Email: eazhar@kau.edu.sa

Abstract
More than two million Muslims visit Makkah, Saudi Arabia, annually to perform the religious rituals of Hajj where the risk of spreading respiratory infections is very common. The aim here was to screen symptomatic pilgrims for Middle East respiratory syndrome coronavirus (MERS-CoV) and other viral etiologies. Thus, 132 nasopharyngeal samples were collected from pilgrims presenting with acute respiratory symptoms at the healthcare facilities in the holy sites during the 5 days of the 2014 Hajj season. Samples were tested using real-time reverse transcription polymerase chain reactions and microarray. Demographic data including age, sex, and country of origin were obtained for all participants. While we did not detect MERS-CoV in any of the samples, several other viruses were detected in 50.8% of the cases. Among the detected viruses, 64.2% of the cases were due to a single-virus infection and 35.8% were due to the co-infections with up to four viruses. The most common respiratory virus was influenza A, followed by non-MERS human coronaviruses, rhinoviruses, and influenza B. Together, we found that it was not MERS-CoV but other respiratory viruses that caused acute respiratory symptoms among pilgrims. The observed high prevalence of influenza viruses underscores the need for more effective surveillance during the Hajj and adoption of stringent vaccination requirements from all pilgrims.

KEYWORDS
Hajj, influenza, Middle East respiratory syndrome-coronavirus, respiratory infections, Saudi Arabia, viruses

1 | INTRODUCTION

Hajj is a 5-day pilgrimage to the city of Makkah in Saudi Arabia performed by Muslims at least once during their lifetime. Each year, more than two million Muslims from around the world travel to Saudi Arabia to perform Hajj in the holy city of Makkah. On the first day, pilgrims start the "Tawaf" by circumambulating the "Holy Kaaba" for seven times, then the "Sa’i" by walking between the two hills of Safa and Marwah in the grand mosque, for seven times for a total of 3 km. Eventually, the pilgrims depart to the tent city of Mina, around 5 km to the east of Makkah, where they spend the night in groups distributed in tents. Upon sunrise of the second day, pilgrims leave to Mount Arafat, where many Muslims ascend the hill of the mount of Mercy and spend the day repenting and praying. At dusk, pilgrims descend from Arafat and arrive in the valley of Muzdalifah where they spend the night in tents and collect small stones for the symbolic stoning of the devil. On the third day, Muslims move to Mina where they stay until the fifth day of Hajj performing the stoning of the devil.
at the Jamaraat pillars in Mina. Finally, they finish their Hajj ritual by going back to the holy mosque in Makkah to perform "Tawaf".

Overcrowding of individuals in such confined settings leads to inevitable prolonged close contact and increases the risk of spreading and acquiring respiratory pathogens among pilgrims, which raises global and public health concerns due to the high potential of international spread of such pathogens. Another important driver of spreading and acquiring respiratory pathogens during Hajj is the great diversity of inbound viruses from around the world that can potentially spread among the immunologically naive hosts. In fact, acute respiratory infections are very common during Hajj and represent the leading cause of the most hospitalizations. It has been suggested that more than one-third of pilgrims will suffer from respiratory symptoms during Hajj mostly due to the respiratory viruses. Most commonly isolated viruses from symptomatic patients during Hajj were human rhinoviruses (hRVs), influenza virus and non-MERS human coronaviruses (hCoVs).

The emergence of the novel Middle East respiratory syndrome coronavirus (MERS-CoV) in Saudi Arabia, its endemicity, and high mortality rates (35%-40%) clearly represent another major public health concern, especially during Hajj. Since 2012, MERS-CoV caused more than 2250 confirmed cases in 27 countries in the Arabian Peninsula, Africa, Asia, Europe, and North America as of December 2018. Furthermore, multiple hospitals and household outbreaks have been reported mostly in the Saudi Arabia. More importantly, most global MERS cases were linked to travel to the Arabian peninsula. Although all surveillance studies during Hajj did not reveal any MERS-CoV infection among pilgrims, serological testing showed positivity in one Turkish pilgrim who suffered from severe pneumonia and died upon ICU admission in Turkey. Similarly, confirmed cases were reported from Dutch pilgrims returning home from the minor pilgrimage "Umrah". While these studies suggest that MERS-CoV might not be problematic during Hajj so far, transmission of MERS-CoV is always possible especially during these mass-gathering events which could further lead to global spread. Therefore, MERS-CoV surveillance is highly warranted among pilgrims during and after Hajj. In this study, we performed enhanced surveillance for MERS-CoV and other respiratory viruses among individuals with severe respiratory manifestation who presented to primary healthcare facilities during 2014 Hajj.

2 | MATERIALS AND METHODS

2.1 | Samples

During the 5 days of 2014 Hajj (from 3 to 7 October), a total of 132 nasopharyngeal (NP) swabs were collected from all pilgrims presenting with acute severe respiratory tract symptoms and suspected for MERS-CoV infection at seven healthcare facilities in Makkah, Mina, and Arafat. Demographic data including information on sex, age, and nationality were collected from all patients. All swabs were collected in virus transport media and were immediately used for MERS-CoV testing on site and remaining samples were stored at ~80°C until further testing for other respiratory viruses at the Special Infectious Agents Unit, King Fahd Medical Research Center, and King Abdulaziz University (Jeddah, Saudi Arabia).

2.2 | MERS-CoV detection

RNA extraction was performed using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. Extracted RNA from all samples was tested for MERS-CoV using real-time reverse transcription polymerase chain reactions targeting upstream region of the E-gene as described previously. Positive and negative (no template) controls were included in all runs.

2.3 | RVP plus infiniti microarray assay

Remaining NP samples were used for complementary DNA (cDNA) synthesis and microarray testing as described previously. Nucleic acid was extracted from all samples and used to synthesize cDNA using SuperScript III First-Strand Synthesis SuperMix Kit (Life Technologies, Carlsbad, CA). All samples were then tested for hCoVs (HKU1, OC43, NL63, and 229E), influenza viruses (flu A, flu B, and flu A/H1N1), hRV (A and B), human parainfluenza viruses (hPIV) (1, 2, 3, and 4), human metapneumovirus (hMPV) (A and B), enterovirus (EV) (A, B, C, and D), human adenoviruses (hAdv) (A, B, C, and E), and human respiratory syncytial virus (hRSV) (A and B) using Infiniti RVP Plus Assay on Infiniti Plus Analyzer (AutoGenomics Inc., Carlsbad, CA) according to manufacturer’s instructions and as previously described. Samples were considered positive when the ratio between the virus and background signals was above the calculated threshold.

2.4 | Statistical analysis

The data were analyzed using the Statistical Package for the Social Science Software (SPSS v20.0; SPSS Inc, Chicago, IL). The χ² and Fisher exact tests were used to compare the proportions and a two-tailed probability value of P < 0.05 was considered statistically significant.

3 | RESULTS

A total of 132 pilgrims presented with severe respiratory symptoms at healthcare facilities in the holy sites during 2014 Hajj season were enrolled in this study. The mean age for all participants was 61.85 years (SD = 13.64; range, 26-95 years) with the majority being between 41 and 80 years (Table 1). The total number of males was 88 (66.7%) with the mean age of 62.73 years (SD = 13.85; range, 26-95 years), and the number of females was 44 (33.3%) with the mean age of 60.05 years (SD = 13.19; range, 30-90 years). Of the total patients, 50.8% (67 of 132) tested positive for one or more viruses with males representing 62.7% (42 of 67) of the virally infected patients compared with females who represented 37.3% (25 of 67) (Table 1). As shown in Table 1, although a majority of positive
patients were older than 60 years, this difference was not significant. No statistical significance was found for comparisons of infection rates among males and females or the different age groups. One hundred and twenty-nine of the patients in this study were from 37 countries mostly from Asia and Africa followed by Europe and North America. Nationalities of three individuals were unknown. As expected, viruses were more commonly detected in patients from countries providing the largest number of pilgrims such as India and Indonesia (Figure 1), however, detected viruses were diverse and we did not observe any specific pattern in circulating viruses in patients from India and Indonesia compared with other countries.

Among those who tested positive, 64.2% (43 of 67) had an infection due to a single respiratory virus compared with 35.8% (24 of 67) who suffered from coinfections with up to four viruses. While MERS-CoV was not detected in any of the tested samples, other viral etiologies were determined (Table 2). The most commonly detected viruses were flu A (27.8%, 27 of 97), hRV A/B (16.5%, 16 of 97), hCoV OC43 (15.5%, 15 of 97), flu B (13.4%, 13 of 97), and hCoV 229E (9.2%, 9 of 97). In single infections, flu A and B were the most frequent followed by non-MERS hCoVs and hRV (Table 2). On the other hand, the most common coinfecting virus was hCoV OC43 with the detection rate of 20.4% (11 of 54) of the coinfecting viruses in which it was detected in 11 out of the 24 coinfected individuals. This was followed by flu A (18.5%, 10 of 54), hRV A/B (18.5%, 10 of 54), hAdv C/E (9.3%, 5 of 54), hCoV 229E (9.3%, 5 of 54), hRSV A/B (7.4%, 4 of 54), and flu B (7.4%, 4 of 54). The most common coinfections were due to the hCoV OC43 with either flu A or flu B (3 of 24 in each case) followed by flu A with either hAdv C or hRV A (2 of 24 in each case) (Table 3). Coinfections with more than two viruses were not uncommon. In fact, four patients had triple concurrent infections, and one patient had a quadruple concurrent infection (Table 3). The remaining nine coinfections were due to the unique combination of respiratory viruses (Table 3). Not surprisingly, flu A, flu B, and hCoV OC43 were the most frequently detected viruses in the most age groups (Table 3). Patterns of detected respiratory viruses suggest

### TABLE 1 Demography of patients with acute respiratory tract infection in Hajj 2014

| Variables         | Infected, N (%) | Noninfected, N (%) | All subjects, N (%) |
|-------------------|-----------------|--------------------|---------------------|
| Total number      | 67 (50.8)       | 65 (49.2)          | 132                 |
| Sex               |                 |                    |                     |
| Male              | 42 (47.7)       | 46 (52.3)          | 88 (66.7)           |
| Female            | 25 (56.8)       | 19 (43.2)          | 44 (33.3)           |
| Age group, y      |                 |                    |                     |
| 21-40             | 7 (53.8)        | 6 (46.2)           | 13 (9.8)            |
| 41-60             | 19 (46.3)       | 22 (53.7)          | 41 (31.1)           |
| 61-80             | 32 (50.8)       | 31 (49.2)          | 63 (47.7)           |
| >81               | 4 (57.1)        | 3 (42.9)           | 7 (5.3)             |
| Unknown           | 5 (62.5)        | 3 (37.5)           | 8 (6.1)             |

*Percent is shown out of the total subject number.

![FIGURE 1](image) Geographical distribution of infected and noninfected pilgrims according to their country of origin.
that the most frequently detected viruses in this study such as flu A, flu B, hCoV OC43, and hRV were circulating during almost all the 5 days of Hajj compared with less common viruses such as hPIV 3, hCoV NL63, and EV (Figure 2).
Most Hajj pilgrims are usually old adults and elderly representing a high-risk group for influenza infection especially with the apparent high prevalence of influenza viruses during Hajj. These individuals are more susceptible to influenza viruses and prone to develop severe diseases. While seasonal influenza vaccination is recommended for all pilgrims, current Hajj regulations and guidelines for influenza vaccination require usage of seasonal trivalent vaccine formulation recommended for people younger than 65 years. These vaccines are known to be less immunogenic and less effective in the elderly compared with younger adults. In addition, several studies have shown low vaccination coverage among pilgrims attending multiple Hajj seasons.\(^9,13,20,26,29,30,39\)

Furthermore, detection of influenza viruses is not uncommon among vaccinated individuals during Hajj or in returning pilgrims, mostly due to a possible mismatch between circulating and vaccine strains.\(^10-16,26,29,30,38,40-42\) Therefore, it is highly suggested to implement and adopt new influenza immunization guidelines for Hajj to improve vaccine coverage and to provide sufficient protection against influenza. Possible changes could include the use of quadrivalent influenza vaccines, high-dose vaccines for people older than 65 years and/or inclusion of both influenza vaccines from the northern and southern hemispheres for people younger than 65 years, especially if the two vaccines are different. Moreover, it might be beneficial to enhance human influenza surveillance during Hajj by including genetic and antigenic characterization of circulating strains to ensure strain match and to anticipate any potential early introduction of influenza viruses into Saudi Arabia. Furthermore, it is suggested that countries with

**TABLE 3** Demographic data of patients with acute respiratory tract infection by pathogens identified in Hajj 2014

| Infecting viruses | Number of patients (n = 67) | Age, y, N (%) | Male (n = 42) | Female (n = 25) |
|-------------------|-----------------------------|---------------|--------------|---------------|
| hCoV OC43         | 4 (6.0)                     | 21-40 (n = 7) | 1 (25.0)     | 2 (50.0)      |
| hCoV 229E         | 4 (6.0)                     | 41-60 (n = 19) | 3 (75.0)     | 2 (50.0)      |
| EV A              | 1 (1.5)                     | >81 (n = 4)   | 0            | 1 (100)       |
| EV D              | 1 (1.5)                     | Unknown (n = 5) | 0            | 1 (100)       |
| hRV A             | 5 (7.5)                     | 21-40 (n = 7) | 2 (40.0)     | 1 (20.0)      |
| hRV B             | 1 (1.5)                     | 41-60 (n = 19) | 0            | 3 (60.0)      |
| Flu A             | 16 (23.9)                   | 41-60 (n = 19) | 7 (43.7)     | 1 (6.3)       |
| Flu B             | 9 (13.4)                    | >81 (n = 4)   | 3 (33.3)     | 1 (11.1)      |
| hPIV 3            | 2 (3.0)                     | Unknown (n = 5) | 0            | 1 (50.0)      |
| Flu A + hRSV A    | 1 (1.5)                     | Male (n = 42) | 0            | 1 (100)       |
| Flu A + hAdV C    | 2 (3.0)                     | Female (n = 25) | 1 (50.0)    | 1 (50.0)      |
| Flu A + hRV A     | 2 (3.0)                     | Male (n = 42) | 1 (50.0)     | 1 (50.0)      |
| Flu A + hCoV 229E | 1 (1.5)                     | Female (n = 25) | 1 (100)   | 1 (50.0)      |
| hCoV OC43 + hAdV C| 1 (1.5)                     | Male (n = 42) | 0            | 1 (100)       |
| hCoV OC43 + flu A | 3 (4.5)                     | Unknown (n = 5) | 1 (33.3)  | 1 (33.3)      |
| hCoV OC43 + flu B | 3 (4.5)                     | Male (n = 42) | 1 (33.3)     | 1 (33.3)      |
| hCoV OC43 + hRV A | 1 (1.5)                     | Male (n = 42) | 0            | 1 (100)       |
| hCoV OC43 + hRV B | 1 (1.5)                     | Unknown (n = 5) | 0            | 1 (100)       |
| hCoV 229E + hRV B | 1 (1.5)                     | Male (n = 42) | 1 (100)      | 1 (100)       |
| hCoV NL63 + hRV A | 1 (1.5)                     | Unknown (n = 5) | 1 (100)  | 1 (100)       |
| EV B + EV D       | 1 (1.5)                     | Male (n = 42) | 1 (100)      | 1 (100)       |
| Flu A H1N1 + hAdV E| 1 (1.5)                    | Unknown (n = 5) | 0            | 1 (100)       |
| hCoV OC43 + hRV A + hRSV B | 1 (1.5) | Male (n = 42) | 0            | 1 (100)       |
| hCoV OC43 + hCoV 229E + flu B | 1 (1.5) | Unknown (n = 5) | 0            | 1 (100)       |
| EV B + hRV A + hRSV B | 1 (1.5) | Male (n = 42) | 1 (100)      | 1 (100)       |
| hCoV 229E + hRV A + hRV B | 1 (1.5) | Unknown (n = 5) | 0            | 1 (100)       |
| hCoV 229E + hRSV B + hAdV C + flu A | 1 (1.5) | Male (n = 42) | 1 (100)      | 1 (100)       |

Abbreviations: EV, enterovirus; hAdV, human adenoviruses; hCoVs, human coronaviruses; hPIV, human parainfluenza viruses; hRSV, human respiratory syncytial virus.
CoV was not detected in any of the patients, a variety of other respiratory viruses has been found in more than half of the patients with many coinfections with multiple viruses. Our observation as well as the previous reports from Hajj indicate that enhanced and active surveillance during Hajj seasons is critical to recognize the wide variety of pathogens that might be involved in Hajj epidemics and to implement proper infection control measures. Importantly, there is an evident risk of influenza infection among pilgrims underscoring the need for targeted, active and continuous surveillance for influenza viruses not only to monitor viral circulation but also to characterize circulating viruses to better understand vaccine effectiveness and to recognize the need to improve current influenza vaccination strategies during Hajj.

CONFLICT OF INTERESTS

The authors declared that there is no conflict of interests.

ORCID

Anwar M. Hashem http://orcid.org/0000-0002-8471-7011

REFERENCES

1. Memish ZA, Zumla A, Alhakeem RF, et al. Hajj: infectious disease surveillance and control. Lancet. 2014;383:2073-2082.
2. Gautret P, Benkouiten S, Al-Tawfiq JA, Memish ZA. Hajj-associated viral respiratory infections: a systematic review. Travel Med Infect Dis. 2016;14:92-109.
3. Ahmed QA, Arabi YM, Memish ZA. Health risks at the Hajj. Lancet. 2006;367:1008-1015.
4. Alzere A. Respiratory tract infection during Hajj. Ann Thorac Med. 2009;4:50-53.
5. Madani TA, Ghabrah TM, Al-Hedaiwy MA, et al. Causes of hospitalization of pilgrims in the Hajj season of the Islamic year 1423 (2003). Ann Saudi Med. 2006;26:346-351.
6. Erdem H, Ak O, Elaldi N, et al. Infections in travellers returning to Turkey from the Arabian peninsula: a retrospective cross-sectional multicenter study. Eur J Clin Microbiol Infect Dis. 2016;35:903-910.
7. Al-Tawfiq JA, Zumla A, Memish ZA. Respiratory tract infections during the annual Hajj: potential risks and mitigation strategies. Curr Opin Pulm Med. 2013;19:192-197.
8. Deris ZZ, Hasan H, Sulaiman SA, Wahab MSA, Naing NN, Othman NH. The prevalence of acute respiratory symptoms and role of protective measures among Malaysian hajj pilgrims. J Travel Med. 2010;17:82-88.
9. Balkhy HH, Memish ZA, Bafaqeer S, Almuneef MA. Influenza a common viral infection among Hajj pilgrims: time for routine surveillance and vaccination. J Travel Med. 2004;11:82.
10. Annan A, Owusu M, Marfo KS, et al. High prevalence of common respiratory viruses and no evidence of Middle East respiratory syndrome coronavirus in Hajj pilgrims returning to Ghana, 2013. Tropical Med Int Health. 2015;20:807-812.
11. Benkouiten S, Charrel R, Belhouchat K, et al. Circulation of respiratory viruses among pilgrims during the 2012 Hajj pilgrimage. Clin Infect Dis. 2013;57:992-1000.
12. Benkouiten S, Charrel R, Belhouchat K, et al. Respiratory viruses and bacteria among pilgrims during the 2013 Hajj. Emerg Infect Dis. 2014;20:1821-1827.
13. Rashid H, Shafi S, Booy R, et al. Influenza and respiratory syncytial virus infections in British Hajj pilgrims. Emerg Health Threats J. 2008;1:e2.
14. Memish ZA, Assiri AM, Hussein R, Alomar I, Stephens G. Detection of respiratory viruses among pilgrims in Saudi Arabia during the time of a declared influenza A(H1N1) pandemic. J Travel Med. 2012;19:15-21.

15. Moattari A, Emami A, Moghadami M, Honavar B. Influenza viral infections among the Iranian Hajj pilgrims returning to Shiraz, Fars province, Iran. Influenza Other Respir Viruses. 2012;6:e77-e79.

16. Ma X, Liu F, Liu L, et al. No MERS-CoV but positive influenza viruses in returning Hajj pilgrims, China. 2013-2015. BMC Infect Dis. 2017;17:715.

17. Al-Abdallat MM, Rha B, Alqasrawi S, et al. Acute respiratory infections among returning Hajj pilgrims-Jordan. 2014. J Clin Virol. 2018;92:34-37.

18. Atabani SF, Wilson S, Overton-Lewis C, et al. Active screening and surveillance in the United Kingdom for Middle East respiratory syndrome coronavirus in returning travellers and pilgrims from the Middle East: a prospective descriptive study for the period 2013-2015. Int J Infect Dis. 2016;47:10-14.

19. Memish ZA, Almasri M, Turkestani A, Al-Shangiti AM, Yezli S. Etiology of severe community-acquired pneumonia during the 2013 Hajj-part of the MERS-CoV surveillance program. Int J Infect Dis. 2014;25:186-190.

20. Barasheed O, Rashid H, Alfelali M, et al. Viral respiratory infections among Hajj pilgrims in 2013. Virol. Sin. 2014;29:364-371.

21. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814-1820.

22. Middle East respiratory syndrome coronavirus (MERS-CoV). www.who.int/emergencies/mers-cov/en/ (accessed December 15, 2017).

23. Assiri A, Abedi GR, Saeed AAB, et al. Multifacility outbreak of Middle East respiratory syndrome in Taif, Saudi Arabia. Emerg Infect Dis. 2016;22:32-40.

24. Al-Dorzhi HM, Alsalam S, Arabi YM. Critically ill patients with Middle East respiratory syndrome coronavirus infection. Crit Care. 2016;20:65.

25. Kim KH, Tandi TE, Choi JW, Moon JM, Kim MS. Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics, and public health implications. J Hosp Infect. 2017;95:207-213.

26. Gautret P, Charrel R, Belhouchat K, et al. Lack of nasal carriage of novel corona virus (HCoV-EMC) in French Hajj pilgrims returning from the Hajj 2012, despite a high rate of respiratory symptoms. Clin Microbiol Infect. 2013;19:E315-E317.

27. Gautret P, Charrel R, Benkouiten S, et al. Lack of MERS coronavirus but prevalence of influenza virus in French pilgrims after 2013 Hajj. Emerg Infect Dis. 2014;20:728-730.

28. Memish ZA, Assiri A, Almasri M, et al. Prevalence of MERS-CoV nasal carriage and compliance with the Saudi health recommendations among pilgrims attending the 2013 Hajj. J Infect Dis. 2014;210:1067-1072.

29. Refaey S, Amin MM, Roguski K, et al. Cross-sectional survey and surveillance for influenza viruses and MERS-CoV among Egyptian pilgrims returning from Hajj during 2012-2015. Influenza Other Respir Viruses. 2017;11:57-60.

30. Koul PA, Mir H, Saha S, et al. Influenza not MERS CoV among returning Hajj and Umrah pilgrims with respiratory illness, Kashmir, north India, 2014-15. Travel Med Infect Dis. 2017;15:45-47.

31. Aberle JH, Popow-Kraupp T, Kreidt P, Lafferl H, Heinz FX, Aberle SW. Influenza A and B viruses but Not MERS-CoV in Hajj pilgrims, Austria, 2014. Emerg Infect Dis. 2015;21:726-727.

32. Kraajj-dirkzwager M, Timen A, Dirksen K, et al. Middle east respiratory syndrome coronavirus (MERS-CoV) infections in two returning travellers in the Netherlands, May 2014. Euro Surveill. 2014;19:pii 20817.

33. Azhar EI, El-Kafrawy SA, Farraj SA, et al. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med. 2014;370:2499-2505.

34. Abdulhaj AA, Basode VK, Hashem AM, et al. Patterns of human respiratory viruses and lack of MERS-coronavirus in patients with acute upper respiratory tract infections in southwestern province of Saudi Arabia. Adv Virol. 2017;2017:4247853-4247857.

35. Yavarian J, Shafiei Jandaghi NZ, Naseri M, et al. Influenza virus but not MERS coronavirus circulation in Iran, 2013-2016: comparison between pilgrims and general population. Travel Med Infect Dis. 2018;21:51-55.

36. Mackay I, Arden K. An opportunistic pathogen afforded ample opportunities: Middle East respiratory syndrome coronavirus. Viruses. 2017;9:369. pii:E369

37. Imani R, Karimi A, Habibian R. Acute respiratory viral infections among Hajj pilgrims who received predeparture vaccination, Egypt. Travel Med Infect Dis. 2014;1268.

38. Mackay I, Shafiei Jandaghi NZ, Naseri M, et al. Influenza virus but not MERS coronavirus circulation in Iran, 2013-2016: comparison between pilgrims and general population. Travel Med Infect Dis. 2018;21:51-55.

39. Imani R, Karimi A, Habibian R. Acute respiratory viral infections among Hajj pilgrims who received predeparture vaccination, Egypt. Emerg Infect Dis. 2011;17:1266-1268.

40. Alfelali M, Khandaker G, Booy R, Rashid H. Mismatching between epidemic and campaign influenza A(H1N1) 2009 and Hajj pilgrims who received predeparture vaccination, Egypt. Emerg Infect Dis. 2011;17:1266-1268.

41. Imani R, Karimi A, Habibian R. Acute respiratory viral infections among Hajj pilgrims who received predeparture vaccination, Egypt. Emerg Infect Dis. 2011;17:1266-1268.

42. Alfelali M, Khandaker G, Booy R, Rashid H. Mismatching between epidemic and campaign influenza A(H1N1) 2009 and Hajj pilgrims who received predeparture vaccination, Egypt. Emerg Infect Dis. 2011;17:1266-1268.

43. Madani TA, Ghabrah TM. Meningococcal, influenza virus, and hepatitis B virus vaccination coverage level among health care workers in Hajj. BMC Infect Dis. 2007;7:80.

44. Kandeel A, Deming M, Elkreem EA, et al. Pandemic (H1N1) 2009 and Hajj pilgrims who received predeparture vaccination, Iran. Emerg Infect Dis. 2009:16:239-242.

45. Alfelali M, Khandaker G, Booy R, Rashid H. Mismatching between epidemic and campaign influenza A(H1N1) 2009 and Hajj pilgrims who received predeparture vaccination, Egypt. Emerg Infect Dis. 2011;17:1266-1268.

46. Madani TA, Ghabrah TM. Meningococcal, influenza virus, and hepatitis B virus vaccination coverage level among health care workers in Hajj. BMC Infect Dis. 2007;7:80.

47. Kandeel A, Deming M, Elkreem EA, et al. Pandemic (H1N1) 2009 and Hajj pilgrims who received predeparture vaccination, Egypt. Emerg Infect Dis. 2011;17:1266-1268.

48. Madani TA, Ghabrah TM. Meningococcal, influenza virus, and hepatitis B virus vaccination coverage level among health care workers in Hajj. BMC Infect Dis. 2007;7:80.

49. Kandeel A, Deming M, Elkreem EA, et al. Pandemic (H1N1) 2009 and Hajj pilgrims who received predeparture vaccination, Egypt. Emerg Infect Dis. 2011;17:1266-1268.

50. Kandeel A, Deming M, Elkreem EA, et al. Pandemic (H1N1) 2009 and Hajj pilgrims who received predeparture vaccination, Egypt. Emerg Infect Dis. 2011;17:1266-1268.